Arcus Biosciences (RCUS) Preferred Stock Liabilities (2017)

Arcus Biosciences' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $226.2 million for Q4 2017.

• In Q4 2017, Preferred Stock Liabilities changed N/A year-over-year to $226.2 million; the TTM figure through Dec 2017 stood at $226.2 million (changed N/A YoY), while the FY2017 annual figure was $226.2 million, up 89.36% from the prior year.
• Preferred Stock Liabilities for Q4 2017 stood at $226.2 million.
• The five-year high for Preferred Stock Liabilities was $226.2 million in Q4 2017, with the low at $226.2 million in Q4 2017.